Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI may help predict endometriosis drug success

NCT ID NCT07446608

Knowledge-focused Sponsor: Chungnam National University Sejong Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether MRI scans can help doctors predict which women with endometriosis will benefit from the drug dienogest. Researchers will follow 48 women aged 19-45 who are starting dienogest for the first time. By comparing MRI images before treatment with changes in pain and quality of life over 12 months, they hope to find imaging clues that identify good responders. The goal is to personalize treatment and avoid ineffective medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include women aged 19 to 45 years who have been clinically diagnosed with endometriosis by an obstetrician-gynecologist. Eligible participants are those who have not received hormonal treatment within the previous 3 months and have never been treated with dienogest. All participants must provide written informed consent prior to enrollment. Patients with contraindications to dienogest, inability to undergo MRI, current or planned pregnancy within 6 months, or poor general medical condition will be excluded.

Ages

19 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants who have received a full explanation of the study and have provided written informed consent * Women aged 19 to 45 years who have been diagnosed with endometriosis by a board-certified obstetrician-gynecologist * Patients who have not received any hormonal treatment within the previous 3 months * Patients who have never been treated with dienogest Exclusion Criteria: * Patients with a history of treatment with dienogest * Patients with contraindications to dienogest * Patients who are unable to undergo magnetic resonance imaging (MRI) (e.g., presence of metallic implants) * Patients who are currently pregnant or planning pregnancy within the next 6 months * Patients with poor general medical condition, as judged by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometriosis, ovarian are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometriosis ovarian endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometriosis, ovarian

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sejong Chungnam National University Hospital

    RECRUITING

    Sejong, Sejong Special Self-Governing City, 30099, South Korea